Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Published version of a preprint
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
H-Ras, K-Ras, and N-Ras regulate cellular growth and survival and are often activated by somatic mutation in human tumors. Although oncogenic lesions occur in a single Ras isoform within individual tumors, it is unclear whether the remaining wild-type isoforms play supporting roles in tumor growth. Here, we show that oncogenic and wild-type Ras isoforms play independent and nonredundant roles within the cell. Oncogenic Ras regulates basal effector pathway signaling, whereas wild-type Ras mediates signaling downstream of activated receptor tyrosine kinases (RTK). We show that both are necessary for exponential growth of Ras-mutant cell lines. Furthermore, we show that oncogenic Ras desensitizes signaling from EGF receptor (EGFR). Depletion of oncogenic Ras with siRNA oligonucleotides relieves this negative feedback, leading to the hyperactivation of EGFR and wild-type Ras signaling. Consistent with this model, combining oncogenic Ras depletion with EGFR inhibition potently increases cell death. Significance: The results of this study highlight a novel role for wild-type Ras signaling in cancer cells harboring oncogenic RAS mutations. Furthermore, these findings reveal that therapeutically targeting oncogenic Ras signaling alone may be ineffective owing to feedback activation of RTKs, and suggest that blocking upstream RTKs in combination with downstream effector pathways may be beneficial in the treatment of Ras-mutant tumors. Cancer Discov; 3(1); 112–23. ©2012 AACR. See related commentary by Hayes and Der, p. 24 This article is highlighted in the In This Issue feature, p. 1
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“this mechanism of action is unlikely to be effective against the second mechanism of adaptive feedback (RTK-driven activation of wild type RAS) (33).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [33]
In the citing paper
“Therefore, genetic depletion of oncogenic RAS with siRNA oligonucleotides relieves this negative feedback, leading to hyperactivation of EGFR and wild-type RAS signaling [41].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [41]
In the citing paper
“Previous studies have shown that oncogenic RAS regulates the basal effector pathway, whereas wild-type RAS mediates signaling downstream of the activated receptor tyrosine kinases [41].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [41]
In the citing paper
“WT RAS alleles have been shown to be critical in maintaining the growth and signaling of RAS-mutant cell lines, especially from extracellular signals through RTKs and flux through the MAPK pathway (Cheng et al., 2021; Young et al., 2013; Zhou et al., 2016).”
From KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy (2022) · cites this paper as Young et al., 2013
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 2×
“Oncogenic RAS alleles differ from their wild-type counterpart by a single missense point mutation that results in an amino acid substitution typically at position 12, 13, or 61 (6, 7).”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 2×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“Oncogenic mutation in any one of the three RAS genes is thought to be sufficient to constitutively activate downstream signaling and confer independence from upstream growth cues (8).”
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 9×
“The aberrant hyperactivation of Ras plays a causal role in human cancer, and an estimated 30% of human tumors harbor oncogenic somatic mutations in HRAS , KRAS , or NRAS ( 5, 6 ).”
InfluentialKinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328 · cited 2×
“However, the response to MEK kinase inhibitors varies across Ras mutant tumors, and clinical efficacy is thought to be limited by feedback activation of the PI3K pathway (14-17).”
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · cited 2×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 1×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2960 · Cited by 819 · cited 1×
“4 INTRODUCTION H-Ras, K-Ras, and N-Ras are founding members of the Ras family of small GTPases, and regulate cell growth, differentiation, and survival (1, 2).”
RAS Interaction with PI3K: More Than Just Another Effector Pathway
Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732 · cited 1×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
The ERK Cascade: Distinct Functions within Various Subcellular Organelles
Wortzel, I., & Seger, R. (2011) · Genes & Cancer · doi:10.1177/1947601911407328 · Cited by 563 · cited 1×
“In its GTP-bound state, Ras interacts with downstream effectors to activate signaling pathways important for cell growth and survival, including the mitogen-activated protein kinase (MAPK) and phosphoinositide 3- kinase (PI3K) pathways (3, 4).”
Regulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K., Bar-Sagi, D., & Philips, M. R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 557
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528 · cited 1×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442 · cited 1×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Self-citationInhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382 · cited 1×
“Efforts to develop drugs that specifically block the activity of oncogenic Ras have been unsuccessful, although this remains an active area of investigation (10, 11).”
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway
Miao, H., Wei, B.-R., Peehl, D. M., Li, Q., Alexandrou, T., Schelling, J. R., Rhim, J. S., Sedor, J. R., Burnett, E., & Wang, B. (2001) · Nature Cell Biology · doi:10.1038/35074604 · Cited by 358 · cited 2×
“8 signaling upon stimulation with its ligand ephrin-A1 (21, 22).”
Ebisuya, M., Kondoh, K., & Nishida, E. (2005) · Journal of Cell Science · doi:10.1242/jcs.02505 · Cited by 331
Rodriguez-Viciana, P., Sabatier, C., & McCormick, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4943-4954.2004 · Cited by 327
Self-citationTherapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323 · cited 2×
“Smallmolecule compounds targeting the MAPK and PI3K effector pathways are currently under clinical investigation, as these pathways have been well-characterized and shown to be critical in mediating Ras-driven tumorigenesis (9, 13, 14).”
Self-citationWildtype Kras2 can inhibit lung carcinogenesis in mice
Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L., Devereux, T. R., et al. (2001) · Nature Genetics · doi:10.1038/ng721 · Cited by 296 · cited 2×
“Several studies show that wild-type Ras can antagonize the transforming potential of its oncogenic counterpart in vitro and in vivo (23-25).”
Gan, Y., Shi, C., Inge, L., Hibner, M., Balducci, J., & Huang, Y. (2010) · Oncogene · doi:10.1038/onc.2010.240 · Cited by 266
Bremner, R., & Balmain, A. (1990) · Cell · doi:10.1016/0092-8674(90)90523-h · Cited by 264 · cited 1×
“14 oncogenic counterpart in a dose-dependent manner in vitro and in vivo (23-25), and demonstrate a strong selective pressure to lose expression of the corresponding wild-type allele of the oncogenic Ras isoform (35-37).”
A conditional feedback loop regulates Ras activity through EphA2
Macrae, M., Neve, R. M., Rodriguez-Viciana, P., Haqq, C., Yeh, J., Chen, C., Gray, J. W., & McCormick, F. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.005 · Cited by 260 · cited 2×
“8 signaling upon stimulation with its ligand ephrin-A1 (21, 22).”
Self-citationGenetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2223 · Cited by 255 · cited 1×
“The finding that oncogenic Ras mediates feedback suppression of RTKs may help explain the observation that KRAS mutant tumors are often resistant to EGFR-based therapies and have variable responses to single-agent MEK inhibitor treatment (12, 14, 46).”
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
Selective activation of p53-mediated tumour suppression in high-grade tumours
Junttila, M. R., Karnezis, A. N., Garcia, D., Madriles, F., Kortlever, R. M., Rostker, F., Brown Swigart, L., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 245 · cited 1×
“14 oncogenic counterpart in a dose-dependent manner in vitro and in vivo (23-25), and demonstrate a strong selective pressure to lose expression of the corresponding wild-type allele of the oncogenic Ras isoform (35-37).”
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183 · cited 4×
“However, the response to MEK kinase inhibitors varies across Ras mutant tumors, and clinical efficacy is thought to be limited by feedback activation of the PI3K pathway (14-17).”
InfluentialSunaga, N., Shames, D. S., Girard, L., Peyton, M., Larsen, J. E., Imai, H., Soh, J., Sato, M., Yanagitani, N., Kaira, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0750 · Cited by 174 · cited 1×
“Indeed, several recent studies show that oncogenic K-Ras desensitizes cells to EGFR activation and inhibition by altering EGFR trafficking, turnover and localization (29, 30, 32, 47-49).”
Guo, H., Miao, H., Gerber, L., Singh, J., Denning, M. F., Gilliam, A. C., & Wang, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0004 · Cited by 139 · cited 1×
“EphA2 knockout mice are significantly more susceptible to chemically-induced skin carcinogenesis driven by an activating mutation in Hras, demonstrating that EphA2 can exert tumor suppressive effects despite the presence of oncogenic Ras (40).”
Yoon, Y., Kim, H., Han, S., Oh, D. Y., Im, S., Bang, Y., & Kim, T. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20607 · Cited by 126
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
To, M. D., Wong, C. E., Karnezis, A. N., Del Rosario, R., Di Lauro, R., & Balmain, A. (2008) · Nature Genetics · doi:10.1038/ng.211 · Cited by 117
Li, X., Huang, Y., Jiang, J., & Frank, S. J. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.08.006 · Cited by 110 · cited 6×
“© 2013 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from Young et al.RESEARCH ARTICLE A RD NRAS Q61H Non-silencing NRAS T24 HRAS G12V siRNA: Non-silencing HRAS Minutes after EGF: – 5 15 30 60 120 – 5 15 30 60 120 – 5 15 30 60 120 – 5 15 30 60 120 – 5 15 30 60 120 – 5 15 30 60 1…”
InfluentialA functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice
To, M. D., Pérez‐Losada, J., Mao, J., Hsu, J., Jacks, T., & Balmain, A. (2006) · Nature Genetics · doi:10.1038/ng1836 · Cited by 72
Yoon, Y.-K., Kim, H.-P., Han, S.-W., Hur, H.-S., Oh, D. Y., Im, S.-A., Bang, Y.-J., & Kim, T.-Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0300 · Cited by 71 · cited 3×
“It has been shown that pharmacological MEK inhibition similarly sensitizes cells to EGF stimulation (17, 27-29).”
Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function.
Huang, D. C., Marshall, C. J., & Hancock, J. F. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.4.2420 · Cited by 69
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer
Li, J., Zhang, Z., Zunyan Dai, Y., Plass, C., Morris, Q., Wang, Y., Wiest, J. S., Anderson, M. W., & You, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206192 · Cited by 58 · cited 1×
“14 oncogenic counterpart in a dose-dependent manner in vitro and in vivo (23-25), and demonstrate a strong selective pressure to lose expression of the corresponding wild-type allele of the oncogenic Ras isoform (35-37).”
Clark, G. J., Quilliam, L. A., Hisaka, M. M., & Der, C. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4887 · Cited by 57 · cited 3×
“© 2013 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from JANUARY 2013 CANCER DISCOVERY | 121 Regulation of Signaling by Wild-type and Oncogenic Ras RESEARCH ARTICLE p120 RasGAP antagonizes the transforming potential of oncogenic Ras in NIH3T3 cells, and that this antagonism is…”
Influentialvan Houdt, W. J., Hoogwater, F. J. H., de Bruijn, M. T., Emmink, B. L., Nijkamp, M. W., Raats, D. A. E., van der Groep, P., van Diest, P., Borel Rinkes, I. H. M., & Kranenburg, O. (2010) · Neoplasia · doi:10.1593/neo.92088 · Cited by 50 · cited 1×
“Indeed, several recent studies show that oncogenic K-Ras desensitizes cells to EGFR activation and inhibition by altering EGFR trafficking, turnover and localization (29, 30, 32, 47-49).”
Cited by
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Self-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
“…the remaining wild-type (WT) RAS proteins present in RAS-mutant cancers in contributing to cancer growth (Grabocka et al., 2014; Lim et al., 2008; Young et al., 2013), although other studies suggest that WT RAS can act as a tumor suppressor (Bremner and Balmain, 1990; Qiu et al., 2011; To et…”
BackgroundResultStephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
“It is also clear that knocking down activated Ras can lead to hyperactivation of upstream pathways, such as EGFR signaling (Young et al., 2013).”
BackgroundSelf-citation
Metadata
- Authors
- Young, A., Lou, D., & McCormick, F.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Cancer Discovery
- Published
- 2013-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 112-123
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1980323101
- Semantic Scholar
- 0fc5d9d29e0913d74b3ea62adbe40a92015d90a3
- Cited by
- 211
- References
- 50
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 8 · 2023: 18 · 2022: 13 · 2021: 14 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 18 · 2016: 14 · 2015: 24 · 2014: 23 · 2013: 15
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS wild-type, Ras isoforms, MAPK signaling, receptor tyrosine kinase, EGFR, negative feedback signaling, combination therapy, EGFR inhibition, tumor cell proliferation
- MeSH terms
- Erlotinib Hydrochloride, Antineoplastic Agents, Cell Cycle, Humans, Neoplasms, Quinazolines, Genes, ras, Apoptosis, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.